Vimarsana
Biggest News Aggregation in the World

Page 13 - Operations Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Operations Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Operations Data Today - Breaking & Trending Today

MYR Group Inc. Announces First-Quarter 2024 Results - Vimarsana News

MYR Group Inc. Announces First-Quarter 2024 Results

THORNTON, Colo., May 01, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the...

ATN Reports First Quarter 2024 Results; Revises Full Year 2024 Outlook - Vimarsana News

ATN Reports First Quarter 2024 Results; Revises Full Year 2024 Outlook

24.04.2024 - “First-to-Fiber” and “Glass & Steel” Strategies Drive Continued Year-Over-Year Growth in High-Speed Data Subscribers and Network Reach First quarter revenues increased 1% to $186.8 millionTotal high-speed broadband subscribers increased by ...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Data from novel proprietary neurotropic adeno-associated virus delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier penetration in non-human primates following intravenous...

Allbirds Reports Fourth Quarter and Full Year 2023 Financial Results; Achieves Q4 Financial Guidance Targets - Vimarsana News

Allbirds Reports Fourth Quarter and Full Year 2023 Financial Results; Achieves Q4 Financial Guidance Targets

Allbirds COO Joe Vernachio Appointed CEO as Company Accelerates Strategic Transformation Plan Company Provides 2024 Outlook SAN FRANCISCO, March 12, 2024 -- Allbirds, Inc. , a global...

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in...